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Guangzhou, ¥82,383(¥74,956-¥89,810) vs. ¥80,799(¥73,545-¥88,054) for Nanjing, and 
¥59,413(¥54,366-¥64,460) vs. ¥57,804(¥52,613-¥62,996) for Xi’an. The ICER of linezolid 
over vancomycin were ¥19,719(-¥143,553-¥320,980), ¥15,532(-¥185,411-¥349,693), 
¥15,904(-¥161,935-¥314,987), and ¥16,145(-¥100,738-¥234,412) per additional treat-
ment success for Beijing, Guangzhou, Nanjing, and Xi’an, respectively. Out of 10,000 
bootstrap simulations, majority cases had greater efficacies and higher costs for lin-
ezolid (in quadrant I of the E-EC plane: Beijing(64%), Guangzhou(59%), Nanjing(61%), 
Xi’an(66%)), more than one third had greater efficacies and lower costs for linezolid 
(linezolid dominated vancomycin: Beijing(33%), Guangzhou(38%), Nanjing(37%), 
Xi’an(32%)); only < 2% had greater efficacies and lower costs for vancomycin in 
all cities (vancomycin dominated linezolid). ConClusions: In this clinical trial 
population, linezolid appears to be cost-effective from Chinese payers’ perspective 
when compared to vancomycin in treating patients with nosocomial pneumonia 
caused by MRSA.
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objeCtives: Respiratory fluoroquinolones are considered to be an important treat-
ment option in hospitalized adults with community-acquired pneumonia (CAP). 
We aimed to compare cost-effectiveness of sequential intravenous to oral therapy 
of CAP with moxifloxacin and levofloxacin ± beta-lactam in a multi-field Russian 
hospital. Methods: Standard search of prospective randomized clinical trials (RCT) 
was performed for the period since 1st Jan 1995 till 31st Dec 2012. RCTs quality 
was assessed by Jadad scale. Three RCTs with direct comparison of moxifloxacin 
vs. levofloxacin±ceftriaxone in adults with CAP required initial intravenous anti-
microbial therapy [Torres A. 2008, File T.M. Jr. 2001, Anzueto A. 2006] were included 
in the analysis. As similar efficacy and safety was shown between comparators a 
cost-minimisation model was applied. Original drugs’ costs were extracted from 
hospital receipt notes of three multi-field hospitals and wholesale prices data-
base (www.pharmindex.ru). Cost of therapy was calculated to respective treatment 
regiments in selected trials: moxifloxacin 400 mg QD vs. levofloxacin 500 mg QD/
BID±ceftriaxone 2 g QD for 11 days. Uncertainty was explored in a series of one- and 
two-way sensitivity analysis. Results: The respective total drug therapy costs per 
patient were as follows: € 249 for moxifloxacin vs. € 161/€ 321 for levofloxacin QD/BID 
and € 419/€ 579 for levofloxacin QD/BID+ceftriaxone. In levofloxacin monotherapy 
regimens the results were sensitive for IV therapy duration and oral/IV levofloxacin 
cost. In both levofloxacin+ceftriaxone regimens the results were insensitive to all 
variables of interest. ConClusions: Moxifloxacin is more cost effective strategy 
then levofloxacin+ceftriaxone for the treatment of hospitalized adults with CAP. The 
higher cost-effectiveness for moxifloxacin vs. levofloxacin monotherapy depends on 
IV therapy duration, levofloxacin regimen and oral/IV levofloxacin cost.
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of lINEzolId wIth cEftazIdImE IN thE maNagEmENt of hosPItalIsEd 
PNEuNomIa IN scotlaNd
van der Scheer F.W.1, Kuessner D.2, de Silva S.3, Posthumus J.2, Bergman G.1
1Mapi, Houten, The Netherlands, 2Basilea Pharmaceutica International Ltd., Basel, Switzerland, 
3Mapi, London, UK
objeCtives: Ceftobiprole is a new i.v. anti-infective, which has bactericidal activity 
against difficult to treat Gram-positive (including multidrug-resistant pneumococci 
and methicillin-resistant Staphylococcus aureus; MRSA) and Gram-negative (includ-
ing Pseudomonas aeruginosa) bacteria, which are important aetiological agents of 
nosocomial pneumonia (NP) and hospitalised community-acquired pneumonia (CAP). 
The objective of this analysis was to estimate the economic value of ceftobiprole (TID) 
compared to linezolid (BID)/ceftazidime (TID) in the treatment of hospitalised pneu-
monia patients in Scotland, when coverage of MRSA and Gram-negative pathogens, 
including P. aeruginosa,is required. Methods: A cost-minimisation analysis, includ-
ing only direct medical (drug) costs, was considered appropriate since the ceftobiprole 
phase 3 trials in NP and CAP demonstrated that ceftobiprole is non-inferior to a 
combination therapy consisting of linezolid and ceftazidime (NP) or ceftriaxone with 
or without linezolid (CAP). The base case model included drug acquisition, treatment 
duration, and administration costs. In additional scenario analyses, the cost-minimi-
sation analysis included ICU and total hospitalisation costs as well. The resource use 
data were derived from the NP trial. Results: Treatment with ceftobiprole resulted in 
a cost-saving of £258 per treated patient compared to linezolid/ceftazidime therapy. 
While no change in the drug budget is estimated, cost-savings are expected due to 
less administration time. Scenario analyses evaluated the reduction in length of ICU 
stay and overall hospital stay that will potentially lead to further cost savings for NHS 
Scotland (-£2,182 and -£904 per treated patient, respectively). ConClusions: This 
economic evaluation shows that ceftobiprole is at least a cost-neutral alternative 
to a combination of linezolid with ceftazidime and provides an effective and safe 
alternative for hospitalised pneumonia patients in Scotland.
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objeCtives: New antiretroviral drugs have a major impact on future treatment 
options for treatment-experienced HIV-patients with antiretroviral resistance. The 
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objeCtives: This systematic review aimed to assess the cost-effectiveness of rou-
tine varicella and herpes zoster vaccination in high-income countries. Methods: 
A PubMed search was performed for identifying English- and German-language 
publications on economic analysis of varicella and herpes zoster (HZ) vaccina-
tion programmes published before May 2013. A study was included if it was a full 
economic evaluation of a routine childhood or adolescent varicella vaccination 
programme and/or a HZ vaccination scheme targeting the elderly and if the study 
reported results for a high-income country as specified by the World Bank. To 
improve comparability between studies and across countries, all cost estimates 
were inflated to 2010 values applying country-specific consumer price indices and 
converted to Euros with the German level of purchasing power using purchasing 
power parities obtained from the Organisation for Economic Co-operation and 
Development. Results: After the study selection process, 37 model-based stud-
ies remained to be included in the review. Routine childhood or adolescent varicella 
vaccination was cost-effective or cost-saving from a payer perspective and always 
cost-saving from a societal perspective when ignoring a potential impact on HZ due 
to exogenous boosting. The inclusion of the impact on HZ led to net QALY losses or 
incremental cost-effectiveness ratios exceeding commonly accepted thresholds. 
Additional HZ vaccination could partially mitigate this effect. Results of the studies 
only focusing on the evaluation of HZ vaccination ranged from EUR 1,200 to 291,240 
per QALY in one study assessing multiple scenarios and from EUR 5,572 to 140,125 
per QALY across all other studies. ConClusions: While cost-effectiveness of HZ 
vaccination was strongly dependent on the age of vaccination, cost-effectiveness 
of varicella vaccination was primarily dependent on the in- or exclusion of the 
potential impact on HZ. As a consequence, clarification on the role of exogenous 
boosting is crucial for decision-making regarding varicella vaccination.
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objeCtives: Gram-positive bacteria cause clinically severe peritonitis and exit-
site infection (ESI) in patients on peritoneal dialysis (PD). Incident PD patients are 
most prone to developing ESI and peritonitis within the first year of dialysis. We 
investigated the potential costs, quality of life, and clinical outcomes of incident PD 
patients with or without regular application of mupirocin on exit-site from the per-
spective of health care provider in Hong Kong. Methods: We designed a decision 
tree to simulate potential outcomes of incident PD patients with and without regular 
application of mupirocin over a period of one year. Outcome measures included total 
direct medical cost per patient, quality-adjusted life-years (QALYs) gained and gram-
positive bacterial infection-related mortality rate. Model inputs were derived from 
literature. Sensitivity analyses evaluated the impact of uncertainty in all model vari-
ables. Results: In base-case analysis, the mupirocin group showed higher expected 
QALYs (0.6496 vs. 0.6456), lower infection-related mortality rate (0.18% vs. 1.64%) 
and lower total cost per patient (USD258 vs. USD1,661) comparing with the control 
group. Rate of gram-positive bacterial peritonitis without mupirocin and the risk of 
gram-positive bacterial peritonitis with mupirocin were identified to be potential 
influential factors. In 10,000 Monte Carlo simulations, mupirocin group was signifi-
cantly (p< 0.001) less costly, gained higher QALYs with lower mortality rate 99.9% of 
the time. ConClusions: Daily application of mupirocin at catheter exit-site during 
the first 12 months of PD seems to be cost-saving and effective in reducing mortality 
of PD-related gram-positive infections as well as improving health-related quality 
of life from the perspective of health care provider in Hong Kong.
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objeCtives: To assess the cost-effectiveness of linezolid versus vancomycin in 
the treatment of NP in four major cities (Beijing, Guangzhou, Nanjing, and Xi’an) 
in China. Methods: We conducted cost-effectiveness analyses from Chinese pay-
ers’ perspective piggybacked to a phase IV, randomized, double-blind, multicenter 
study (Wunderink et al, CID 2012) in MRSA-NP patients (microbiologic confirmed 
intent-to-treat cohort). Efficacy was measured by treatment success (defined as 
Cure+Improvement) at the end of study (i.e., 7-30 days after the end of treatment). 
Direct medical costs from four cities in China (¥, 2012) were calculated from the 
health care resource use data collected from the trial, including study medica-
tion, hospitalization, mechanical ventilation, and continuous renal replacement 
therapy. Nonparametric bootstrapping method was used to calculate confi-
dence intervals (CI) for costs, efficacy, and incremental cost-effectiveness ratios 
(ICER). Results: Data from 391 patients (186 linezolid, 205 vancomycin) were ana-
lyzed. More linezolid patients achieved treatment success vs. vancomycin patients 
[mean (95% CI)]: 55% (48.3%-61.9%) vs. 45% (38%-52.3%). The total treatment costs 
of linezolid vs. vancomycin were: ¥79,551(¥72,421-¥86,680) vs. ¥77,587(¥70,656-
¥84,519) for Beijing, ¥90,995(¥82,598-¥99,393) vs. ¥89,448(¥81,295-¥97,601) for 
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SEK. ConClusions: Given a willingness-to-pay threshold of 600,000 SEK/QALY, 
posaconazole is likely to be cost-effective for preventing IFIs in GVHD-patients 
compared to fluconazole.
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Israeli ministry of health guidelines for antenatal screening recommend HIV test-
ing only in women belonging to high risk groups. This policy resulted in the last 
10 years in an annual average of two infected children from unidentified Israeli 
women. objeCtives: To evaluate an alternative strategy of universal screen-
ing using a cost utility analysis. Methods: A budget impact analysis was first 
conducted to evaluate the cost of introducing universal screening using a payer 
perspective. Following, a cost-utility analysis (CUA) was carried out to evaluate 
long term effects of such strategy, compared with current policy. The model was 
comprised of two steps: a decision tree simulating the period from pregnancy 
to delivery and a successive Markov model simulating life expectancy of the 
newborn. Screening test sensitivity and specificity were regarded as 99.94% and 
99.5% respectively. Probabilities for having HIV for the low and high-risk popula-
tions were based on experts’ opinion. They were then adjusted to allow model 
calibration to reflect real-life finding as presented above. The cost of the screen-
ing test was US$ 5.5. Other costs included physician visits, viral load and blood 
tests, CD4 counts, and medications. QALY weights were 0.83 for HIV and 0.7 for 
AIDS. Results: Probabilities for having HIV for the low and high-risk populations 
were 0.0215% and 1% respectively. The incremental cost of the universal screening 
over current policy for an annual cohort of 166,000 Israeli pregnant women was 
US$1 million, reflecting a cost of $500,000 per a case of an HIV+ baby avoided. For 
this cohort, an incremental 18 QALYS were projected over a 90 year time hori-
zon with an incremental cost-effectiveness ratio of US$ -30,000. ConClusions: 
Universal Antenatal HIV screening should be implemented in Israel. The current 
policy of screening identified high-risk women is both less effective and more 
costly.
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objeCtives: In France, rilpivirine is reimbursed for HIV-1-infected treatment-
naïve patients with VL≤ 100,000 copies/mL for whom the use of efavirenz is not 
appropriate. This analysis aims to compare costs and outcomes of rilpivirine vs. 
other third antiretroviral (ARVs) agent recommended in France (in addition to two 
NRTIS). Methods: A cohort-based Markov model with four therapy lines and six 
health states based on CD4+ cell-count ranges was developed based on 1-year 
cycle and a 5-year time horizon. First-line efficacy data at 48 and 96 weeks was 
first assumed to be similar across treatments, and subsequently set to statisti-
cally significantly different (SSD) values from phase-III trial analyses of patients 
with VL≤ 100,000 copies/mL. Costs of first-line treatments were obtained from the 
French National Formulary. Costs associated with subsequent treatments and 
CD4+ health states were derived from a French cost-effectiveness analysis. Other 
clinical inputs, HIV-related mortality rates and utility were derived from inter-
national publications. Outcomes and costs were discounted at 4%. Robustness 
of results was assessed using sensitivity analyses (e.g. using efficacy values 
no SSD). Results: All phase-III trials (i.e. ECHO/THRIVE, STARTMRK, CASTLE, 
ARTEMIS, KLEAN, GEMINI, 2NN) demonstrated a non-inferior antiviral efficacy 
between arms. In patients with VL≤ 100,000 copies/mL, response rates were avail-
able for rilpivirine (1-year: 90,2%; 2-year: 84,0%), ritonavir-boosted (/r) darunavir 
(1-year: 79,5%; 2-year: 76,1%), lopinavir/r (1-year: 84,5%; 2-year: 75,2%), atazanavir/r 
(1-year: 82%; 2-year: 75%), fosamprenavir/r (1-year: 67%) and raltegravir (1-year: 
93%). CD4+ cell count changes per mm3 were available for atazanavir/r (1-year: 
+179; 2-year: +243), lopinavir/r (1-year: +194; 2-year: +267), rilpivirine (1-year: +185) 
and raltegravir (1-year: +180). Rilpivirine was the less expensive option in the cost-
minimisation analyses and dominated all treatments in the cost-effectiveness 
analyses when considering SSD efficacy values. ConClusions: The analysis pro-
vided health economic results for HIV-1-infected treatment-naïve patients with 
VL≤ 100,000 copies/mL favoring rilpivirine over all other ARVs analysed.
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objeCtives: To assess the cost-effectiveness of telaprevir (TVR) added to peginter-
feron and ribavirin (PR) therapy in treatment naive (TN) and experienced (TE) 
genotype 1 chronic HCV patients in Poland. Methods: Analysis was based on 
a previously validated Markov model, describing the progression of the disease 
over a lifetime, adapted to population characteristics specific to Poland and cost 
parameters obtained via questionnaire studies completed by clinical practition-
ers. The model comprises the following health states: mild CHC without/with 
SVR (remission), moderate CHC without/with SVR, cirrhosis without/with SVR, 
antiviral therapy, decompensated cirrhosis, HCC, liver transplantation, post-liver 
transplant, CHC related death. The following treatment strategies were considered: 
PEG++ RBV therapy for 48 weeks; TVR for 12 weeks with PEG+RBV (response-guided 
therapy in TN and 48 weeks in TE patients). A cost-utility analysis was conducted 
goal of this study was to perform economic evaluation of maraviroc compared with 
other new antiretroviral agents, such as raltegravir, darunavir and enfuvirtide for 
treatment-experience patients with HIV infection in Russia. Methods: Indirect 
comparison was performed to assess the relative clinical efficacy and safety of 
compared drugs, all in combination with optimized background therapy (OBT). 
A mathematical model was created in Microsoft Excel software to estimate the 
direct medical costs of: compared drugs, an average OBT regimen and routine 
outpatient follow-up (including visits to specialists and diagnostic tests). Drug 
and medical services cost calculations were based on registered prices from the 
list of vital and essential drugs and financial standards of regional program of 
national guarantees for the provision of free medical care to Russian citizens in 
Moscow in 2012, respectively. The obtained results were tested in sensitivity analy-
sis. Results: According to indirect comparison results, there were no statistically 
significant differences between maraviroc, raltegravir, darunavir and enfuvirtide 
neither by the undetectable HIV RNA level nor CD4(+) cell-count changes. The rate 
of adverse events was comparable (except enfuvirtide that has more injection-site 
reactions). Maraviroc-containing regimen compared with raltegravir-, darunavir- 
and enfuvirtide-containing regimen is associated with reduced costs and saves 
an average 177 764.16 rub (€ 4 209.94), 59 929.92 rub (€ 1 419.30) and 462 295.92 rub 
(€ 10 948.42) per 48 weeks of therapy, and 340 714.64 rub (€ 8 069.05) and 114 865.68 
rub (€ 2 720.33) and 886 067.18 rub (€ 20 984.47) per 96 weeks of therapy per patient, 
respectively. Results were robust in one-way sensitivity analyses. ConClusions: 
The analysis showed that maraviroc compared with darunavir, raltegravir and 
enfuvirtide is a cost-saving treatment option for CCR5 tropic treatment-experi-
enced patients in Russia.
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objeCtives: The addition of boceprevir (BOC) to peginterferon–ribavirin (PR) 
resulted in significantly higher rates of sustained virologic response in naive or 
pretreated patients with the chronic hepatitis C virus (HCV) genotype 1 infection, as 
compared with PR alone. The objective is to project the long-term clinical benefits 
and estimate the cost-effectiveness of the treatment strategies recommended in 
the BOC label compared with PR alone. Methods: A Markov model was created 
to estimate the expected costs and quality adjusted life-years (QALYs) associated 
with the BOC tritherapy and PR. The model simulates the treatment regimens and 
the natural history of the chronic HCV to project the lifetime cumulative incidence 
of advanced liver-related diseases (decompensated cirrhosis (DC), hepatocellular 
carcinoma (HCC)) and liver transplant. Series of 30 cohorts representing all com-
binations of pre-specified patient characteristics progress through the model. The 
baseline characteristics used to define the cohorts are: naive/pretreated, age, gender, 
baseline fibrosis score and race cohort for the treatment naive population only. 
Separate analyses were run for naive and pretreated patients. The distribution of 
baseline fibrosis score for each analysis was based on the subjects enrolled in the 
clinical trials; the average age and distribution of race cohort were based on French 
observational study (F. Roudot Thoraval, ADEQUATION, AFEF 2009). The comparator 
was PR (48 weeks). Results: The model predicted relative reductions in patients 
treated with BOC vs PR alone: 33% and 32% in DC/HCC in naive patients and also 
46% and 53% in DC/HCC in pretreated patients. The ICER of BOC-based therapy 
compared with PR were 15,681€ /QALY for naive patients and 10,563€ /QALY for pre-
treated patients. ConClusions: Compared with PR, boceprevir-based treatment is 
projected to substantially reduce the burden of liver complications associated with 
the chronic hepatitis C virus genotype 1 and is highly cost-effective if a threshold 
of 50,000€ /QALY is assumed.
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objeCtives: In allogeneic transplant (allo-SCT) recipients with graft-versus-host 
disease (GVHD) the risk of contracting an invasive fungal infection (IFI) is high and 
antifungal prophylaxis to prevent IFIs is routinely given. Fluconazole, has been 
standard antifungal prophylaxis in GVHD-patients in Sweden. Recently many 
Swedish centers have switched from fluconazole, which lacks efficacy against 
Aspergillus, to posaconazole, for the prevention of IFIs in GVHD-patients receiving 
moderate to high doses of glucocorticoids. Although, the superior efficacy of posa-
conazole vs. fluconazole in preventing IFIs have been demonstrated in this clinical 
setting, the cost-effectiveness of posaconazole vs. fluconazole for GVHD-patients in 
Sweden has not been established. The aim of this analysis is to estimate the cost-
effectiveness of posacoanzole vs. fluconazole prophylaxis in allo-SCT recipients 
with severe GVHD receiving immunosuppressive therapy in Sweden. Methods: 
A decision-analytic model was used to determine life-time outcomes of patients 
with GVHD at high risk of contracting IFIs. The model outcomes were quality 
adjusted life years (QALYs), costs associated with IFI-prophylaxis and treatment 
of IFIs and the incremental cost-utility ratio. The efficacy data were gathered from 
a clinical trial comparing posaconazole with fluconazole prophylaxis in patients 
with GVHD. The resource use for treatment of IFIs was gathered by expert opin-
ion. Utility, mortality and unit costs were gathered from the literature. To assess 
the uncertainty of the modeled outcomes a probabilistic sensitivity analysis (PSA) 
was developed. Results: The incremental cost-utility ratio of posaconazole vs. 
fluconazole for the prevention of IFI in GVHD-patients in Sweden was 541,628 SEK/
QALY. The PSA showed a 56.4% probability for a cost per QALY less than 600,000 
